Phase II trial of amonafide in previously treated patients with advanced ovarian cancer

A Southwest Oncology Group study

Holly H. Gallion, P. Y. Liu, David S Alberts, Robert V. O'Toole, Janet O'Sullivan, Glenn Mills, Harriet O. Smith, Harry E. Hynes

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Twenty-three patients with metastatic or recurrent Stage III or IV epithelial ovarian cancer who were refractory to or relapsed following previous chemotherapy with cisplatin or a cisplatin analog were entered into a phase II study of amonafide. The starting dose of amonafide was 300 mg/m2 delivered daily over 1 hr by intravenous infusion. In the absence of myelosuppression, the dose of amonafide was escalated by increments of 75 mg/m2 to a maximum of 450 mg/m2. There were 19 eligible and 17 fully evaluable patients. Grade 3 or 4 leukopenia occurred in 14 (74%) patients and grade 3 or 4 thrombocytopenia in 6 (32%) patients. No objective complete or partial responses were observed. Four patients had stable disease for 3, 4, 4.5, and 6 months, respectively. Therefore, amonafide in the doses used in the present trial does not have significant activity in previously treated patients with ovarian cancer.

Original languageEnglish (US)
Pages (from-to)230-232
Number of pages3
JournalGynecologic Oncology
Volume46
Issue number2
DOIs
StatePublished - 1992

Fingerprint

amonafide
Ovarian Neoplasms
Cisplatin
Leukopenia
Intravenous Infusions
Drug Therapy

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Phase II trial of amonafide in previously treated patients with advanced ovarian cancer : A Southwest Oncology Group study. / Gallion, Holly H.; Liu, P. Y.; Alberts, David S; O'Toole, Robert V.; O'Sullivan, Janet; Mills, Glenn; Smith, Harriet O.; Hynes, Harry E.

In: Gynecologic Oncology, Vol. 46, No. 2, 1992, p. 230-232.

Research output: Contribution to journalArticle

Gallion, Holly H. ; Liu, P. Y. ; Alberts, David S ; O'Toole, Robert V. ; O'Sullivan, Janet ; Mills, Glenn ; Smith, Harriet O. ; Hynes, Harry E. / Phase II trial of amonafide in previously treated patients with advanced ovarian cancer : A Southwest Oncology Group study. In: Gynecologic Oncology. 1992 ; Vol. 46, No. 2. pp. 230-232.
@article{4f36ea7905074a2b8fd7e81cf2666258,
title = "Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: A Southwest Oncology Group study",
abstract = "Twenty-three patients with metastatic or recurrent Stage III or IV epithelial ovarian cancer who were refractory to or relapsed following previous chemotherapy with cisplatin or a cisplatin analog were entered into a phase II study of amonafide. The starting dose of amonafide was 300 mg/m2 delivered daily over 1 hr by intravenous infusion. In the absence of myelosuppression, the dose of amonafide was escalated by increments of 75 mg/m2 to a maximum of 450 mg/m2. There were 19 eligible and 17 fully evaluable patients. Grade 3 or 4 leukopenia occurred in 14 (74{\%}) patients and grade 3 or 4 thrombocytopenia in 6 (32{\%}) patients. No objective complete or partial responses were observed. Four patients had stable disease for 3, 4, 4.5, and 6 months, respectively. Therefore, amonafide in the doses used in the present trial does not have significant activity in previously treated patients with ovarian cancer.",
author = "Gallion, {Holly H.} and Liu, {P. Y.} and Alberts, {David S} and O'Toole, {Robert V.} and Janet O'Sullivan and Glenn Mills and Smith, {Harriet O.} and Hynes, {Harry E.}",
year = "1992",
doi = "10.1016/0090-8258(92)90261-G",
language = "English (US)",
volume = "46",
pages = "230--232",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Phase II trial of amonafide in previously treated patients with advanced ovarian cancer

T2 - A Southwest Oncology Group study

AU - Gallion, Holly H.

AU - Liu, P. Y.

AU - Alberts, David S

AU - O'Toole, Robert V.

AU - O'Sullivan, Janet

AU - Mills, Glenn

AU - Smith, Harriet O.

AU - Hynes, Harry E.

PY - 1992

Y1 - 1992

N2 - Twenty-three patients with metastatic or recurrent Stage III or IV epithelial ovarian cancer who were refractory to or relapsed following previous chemotherapy with cisplatin or a cisplatin analog were entered into a phase II study of amonafide. The starting dose of amonafide was 300 mg/m2 delivered daily over 1 hr by intravenous infusion. In the absence of myelosuppression, the dose of amonafide was escalated by increments of 75 mg/m2 to a maximum of 450 mg/m2. There were 19 eligible and 17 fully evaluable patients. Grade 3 or 4 leukopenia occurred in 14 (74%) patients and grade 3 or 4 thrombocytopenia in 6 (32%) patients. No objective complete or partial responses were observed. Four patients had stable disease for 3, 4, 4.5, and 6 months, respectively. Therefore, amonafide in the doses used in the present trial does not have significant activity in previously treated patients with ovarian cancer.

AB - Twenty-three patients with metastatic or recurrent Stage III or IV epithelial ovarian cancer who were refractory to or relapsed following previous chemotherapy with cisplatin or a cisplatin analog were entered into a phase II study of amonafide. The starting dose of amonafide was 300 mg/m2 delivered daily over 1 hr by intravenous infusion. In the absence of myelosuppression, the dose of amonafide was escalated by increments of 75 mg/m2 to a maximum of 450 mg/m2. There were 19 eligible and 17 fully evaluable patients. Grade 3 or 4 leukopenia occurred in 14 (74%) patients and grade 3 or 4 thrombocytopenia in 6 (32%) patients. No objective complete or partial responses were observed. Four patients had stable disease for 3, 4, 4.5, and 6 months, respectively. Therefore, amonafide in the doses used in the present trial does not have significant activity in previously treated patients with ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=0026786770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026786770&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(92)90261-G

DO - 10.1016/0090-8258(92)90261-G

M3 - Article

VL - 46

SP - 230

EP - 232

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -